Zafgen Inc (NASDAQ:ZFGN) shot up 1% on Friday . The stock traded as high as $5.66 and last traded at $5.13. 220,400 shares were traded during mid-day trading, an increase of 2% from the average session volume of 215,400 shares. The stock had previously closed at $5.18.

Several brokerages have weighed in on ZFGN. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research report on Saturday, November 11th. ValuEngine cut Zafgen from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $6.63.

The stock has a market cap of $152.56, a P/E ratio of -3.07 and a beta of -1.25.

Zafgen (NASDAQ:ZFGN) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.12. equities analysts predict that Zafgen Inc will post -2.02 EPS for the current fiscal year.

In other Zafgen news, Director Frances K. Heller purchased 10,000 shares of the firm’s stock in a transaction dated Friday, October 13th. The stock was bought at an average price of $3.90 per share, with a total value of $39,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 21.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in ZFGN. GSA Capital Partners LLP bought a new position in shares of Zafgen in the second quarter worth $259,000. OxFORD Asset Management LLP bought a new position in shares of Zafgen in the second quarter worth $364,000. Goldman Sachs Group Inc. grew its stake in shares of Zafgen by 1,701.5% in the second quarter. Goldman Sachs Group Inc. now owns 197,287 shares of the biopharmaceutical company’s stock worth $692,000 after purchasing an additional 186,336 shares in the last quarter. Mangrove Partners bought a new position in Zafgen during the third quarter valued at about $1,971,000. Finally, Dimensional Fund Advisors LP boosted its stake in Zafgen by 31.8% during the second quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock valued at $2,050,000 after buying an additional 140,848 shares in the last quarter. 48.60% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was first posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with Analyst Ratings Network's FREE daily email newsletter.